Glykos
Glykos is a late preclinical stage biopharmaceutical company working on best-in-class ADCs with outstanding therapeutic index. Glykos has fully developed auristatin, anthracyclin and exatecan linker-payloads for ADC generation, as well as hydrophilic linker for application with novel payloads.
Glykos’ pipeline has three preclinical ADC candidates. GLK-10 is directed to HER2-expressing solid tumors, GLK-21 targets a non-disclosed melanoma antigen, and GLK-33 is an anti-CD33 auristatin ADC against AML. We welcome co-development opportunities with these and novel ADCs.
